Johnson & Johnson (NYSE: JNJ) announces that it has successfully completed the acquisition of Yellow Jersey, a demerged subsidiary of Numab Therapeutics to secure the global rights to NM26, a novel, investigational first-in-class bispecific antibody, in an all-cash transaction of approximately $1.25 billion, as announced on May 28, 2024. NM26, which is ready to enter Phase 2 studies in atopic dermatitis (AD), targets two clinically proven pathways, IL-4R alpha subunit (IL-4Rα) and IL-31, which trigger Th2-mediated skin inflammation and skin itch, respectively.
Read the full article: Johnson & Johnson Strengthens Pipeline to Lead in Atopic Dermatitis with the Completion of the Acquisition of Yellow Jersey Therapeutics, Gaining Ownership of NM26 //
Source: https://www.businesswire.com/news/home/20240711820115/en/Johnson-Johnson-Strengthens-Pipeline-to-Lead-in-Atopic-Dermatitis-With-the-Completion-of-the-Acquisition-of-Yellow-Jersey-Therapeutics-Gaining-Ownership-of-NM26